Short answer
Nkarta, Inc. (NKTX) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$28M
- +13.0% YoY
- EPS (diluted)
- −$0.37
- +14.0% YoY
Source: XBRL data from the Nkarta, Inc. (NKTX) Q1 2026 10-Q on SEC EDGAR. USD.
Nkarta, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No product revenue; no approved products or profitability
- Significant historical losses; continued losses expected for foreseeable future
- Additional capital required, potentially causing dilution or restricting operations
- Clinical success dependent on NKX019 and CAR NK-cell platform
- Key headwinds: clinical delays, manufacturing complexity, regulatory approvals, and limited autoimmune-disease data
Risk Factors
- New or changed risks not identifiable; company states 10-K risks unchanged substantively except asterisk-designated factors
- Continuing losses: net loss $27.8 million for Q1 2026 and accumulated deficit $676.1 million as of March 31, 2026
- Capital access: $266.7 million in cash, restricted cash, equivalents and investments, with additional financing required for pivotal trials
- Regulatory risk: no NK-based cell therapy approved commercially, potentially lengthening review and increasing development costs
- Clinical risk: NKX019 hematologic-malignancy programs deprioritized after data and competitive pressures, with no further enrollment planned
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nkarta, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.